Tratamiento de la osteoporosisosteoporosis en la mujer premenopáusica y posmenopáusica. Osteoporosis en el varón

  1. Díaz-Guerra, G. Martínez
  2. Iglesias, S. Guadalix
  3. Miguel, G. Allo
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2018

Título del ejemplar: Enfermedades óseas Osteoporosis. Paget óseo. Síndrome de dolor regional complejo

Serie: 12

Número: 60

Páginas: 3506-3514

Tipo: Artículo

DOI: 10.1016/J.MED.2018.06.019 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

The treatment of osteoporosis should be comprehensive and include lifestyle measures, physical exercise, appropriate calcium and vitamin D intake and, if indicated, drug treatment. At present, there are various therapeutic options whose efficacy and safety have been well contrasted, especially for osteoporosis in postmenopausal women. Oral bisphosphonates (alendronate, risedronate) are the treatment of choice in most cases, but there are other options (teriparatide, denosumab, intravenous zoledronate) which should be used on a very individual basis, depending on factors such as age, the presence or otherwise of frailty fractures, comorbidities, etc. Osteoporosis is a chronic disease that requires long-term treatment and follow-up. However, the duration of drug treatment and the possibility of discontinuing and/or replacing a drug for another are decisions that require in-depth knowledge of the patient's clinical circumstances, which can change throughout the course of the disease, and of the benefit-risk profile of the different drugs. Osteoporosis in premenopausal women and men is usually secondary to underlying disease. The baseline disease should always be treated, although the same recommendations for calcium and vitamin D intake and physical exercise still apply. The current drugs for women of reproductive age have major limitations, and are reserved for particularly severe cases (frailty fractures, for example).

Referencias bibliográficas

  • Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Ran-dall S. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos. 2014;25:2359-81.
  • Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016. Endocr Pract. 2016 Sep 2;22Suppl4:1-42.
  • Del Río L, Tebé C, Johansson H, Di Gregorio S, Estrada D, Espallargués M. Evaluación del riesgo absoluto de fractura mediante herramienta FRAX®en una cohorte española. Rev Osteoporos Metab Miner. 2011;3:85-94.
  • González-Macías J, Marín F, Vila J, Díez-Pérez A. Probability of fractures predicted by FRAX®and observed incidence in the Spanish ECOSAP Study cohort. Bone. 2012;50:373-7.
  • Sosa Henríquez M, Gómez de Tejada MJ. Osteoporosis. Medicine. 2016; 12(16):900-8
  • Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254-62.
  • Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD000333.
  • Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10):711-23.
  • Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729.
  • Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1.
  • Black DM, Kelly MP, Genant HK, , Palermo L, Eastell R, Bucci-Rechtweg C. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761-71.
  • Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.
  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756.
  • Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773.
  • Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open label extension. Lancet Diabetes Endocrinol. 2017;5(7):513.
  • Block GA, Bone HG, Fang L, Lee E, Padhi D. A single dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27:1471-9.
  • Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222.
  • Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291.
  • Cummings SR, Ferrari S, Eastell R, Gilchrist N, Beck Jensen JE, Mc-Clung M. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo controlled FREEDOM Trial and its extension. J Bone Miner Res 2018;33:190-8.
  • Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B4, Eriksen EF5, Guañabens N. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105;11-7.
  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Effect of parathyroid hormone (1-34) on fractures and bone min-eral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434.
  • Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, Kapetanos G, Kocjan T. Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24 month results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int. 2016;99(3):259-71.
  • Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, ZanchettaJR. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int. 2006;17(2):273-80.
  • Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391 (10117):230-40.
  • Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA. Managing osteoporosis in patients on long term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16.
  • González-Macías J, Del Pino-Montes J, Olmos JM, Nogués X, en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigaciones Óseas y Metabolismo Mineral [3ª versión actualizada]. Rev Clin Esp. 2015;215(9):515-26.
  • Qaseem A, Forciea MA, McLean RM, Denberg TD. Treatment of Low Bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:818-39.
  • Cotts KG, Cifu AS. Treatment of osteoporosis. JAMA. 2018;319:1040-1.
  • Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM. Denosumab and teriparatide transitions in postmenopausal os-teoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386:1147-55.
  • McClung MR. Using osteoporosis therapies in combination. Curr Osteoporos Rep. 2017;15:343-52.
  • Cosman F, Nieves JW, Dempster D. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32:198-202.
  • Nayak S, Greenspan SL. Osteoporosis treatment efficacy for men: a sys-tematic review and meta-analysis. J Am Geriatr Soc. 2017;65:490-5.
  • Chen L, Wang G, Zheng F, Zhao H, Li H. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26:2355-63.
  • Langhdal B, Teglbjaerg CS, Ho P, Chapurlat R, Czerwinski E, Kendler DL. A 24 month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: Results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100:1335-42.
  • Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55.
  • Varsavsky M, Romero M, Avila V, Becerra A, García A, Martínez G. Documento de consenso de osteoporosis del varón. Endocrinol Diabetes Nutr 2018;65(S1):9-16.
  • Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.
  • Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M. Teriparatide versus alendronate for treating glucocorticoid induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095-104.
Fuente de los datos: Dialnet